Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7273053 | 0.86 | ALDH1A1 (0.54) | ALDH1A1AHRCA12CA1CA4 | |
| SCHEMBL8630858 | 0.83 | ALDH1A1 (0.51) | ALDH1A1AHRCA12CA1CA4 | |
| SCHEMBL657580 | 0.82 | ALDH1A1 (0.46) | ALDH1A1RAB9AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4089436 | 0.82 | MAOB (0.47) | ALDH1A1RELAESR1AHRPTGS2 | |
| SCHEMBL342467 | 0.82 | NQO1 (0.64) | ALDH1A1RELAESR1AHRNQO1 | |
| SCHEMBL4749153 | 0.82 | PLA2G4A (0.51) | ALDH1A1AHRCA12CA1CA4 | |
| SCHEMBL29629327 | 0.82 | NQO1 (0.68) | ALDH1A1RELAAKR1C3AKR1C2CA12 | |
| SCHEMBL4750053 | 0.82 | PLA2G4A (0.51) | ALDH1A1AHRCA12CA1CA4 | |
| SCHEMBL4745997 | 0.82 | PLA2G4A (0.51) | ALDH1A1AHRCA12CA1CA4 | |
| SCHEMBL4745749 | 0.82 | PLA2G4A (0.51) | ALDH1A1AHRCA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112266327-A | Method for synthesizing beta-hydroxycarbonyl compound by catalyzing asymmetric Aldol reaction in aqueous phase | 昆明理工大学 | 2021-01-26 | — | — | CN | claimed |
| CN-117624062-A | Barbiturates structure-containing compound and preparation method and application thereof | 武汉大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-112266327-B | Method for synthesizing beta-hydroxycarbonyl compound by catalyzing asymmetric Aldol reaction in aqueous phase | 昆明理工大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-112266327-A | Method for synthesizing beta-hydroxycarbonyl compound by catalyzing asymmetric Aldol reaction in aqueous phase | 昆明理工大学 | 2021-01-26 | — | — | CN | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9518026-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-31 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-4000275-A | BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES | ELI LILLY AND COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3987116-A | ETHYNYLARYL COMPOUNDS AND DERIVATIVES THEREOF | WILLIAM H. RORER, INC. (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 3674/4885RELA 2645/4885ESR1 2629/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | ALDH1A1 3165/4885RELA 1080/4885ESR1 4445/4885 |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | PCK1, DCK, CILK1 | ALDH1A1 4033/4885RELA 4540/4885ESR1 4771/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | ALDH1A1 3055/4885RELA 1066/4885ESR1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.